A detailed history of Commodore Capital LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Commodore Capital LP holds 2,528,032 shares of VRDN stock, worth $62.5 Million. This represents 2.95% of its overall portfolio holdings.

Number of Shares
2,528,032
Previous 1,934,653 30.67%
Holding current value
$62.5 Million
Previous $33.9 Million 2.91%
% of portfolio
2.95%
Previous 2.93%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $6.88 Million - $10.2 Million
593,379 Added 30.67%
2,528,032 $32.9 Million
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $180,795 - $251,991
10,579 Added 0.55%
1,934,653 $33.9 Million
Q4 2023

Feb 14, 2024

SELL
$11.12 - $22.5 $3.07 Million - $6.21 Million
-275,926 Reduced 12.54%
1,924,074 $41.9 Million
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $233,396 - $306,817
10,341 Added 0.47%
2,200,000 $52.3 Million
Q1 2023

May 15, 2023

BUY
$25.04 - $37.6 $4.24 Million - $6.37 Million
169,493 Added 8.39%
2,189,659 $55.7 Million
Q4 2022

Feb 14, 2023

SELL
$18.78 - $29.74 $12.7 Million - $20.1 Million
-676,174 Reduced 25.08%
2,020,166 $59 Million
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $11.3 Million - $27 Million
1,057,731 Added 64.55%
2,696,340 $55.3 Million
Q2 2022

Aug 15, 2022

BUY
$9.55 - $19.0 $6.56 Million - $13.1 Million
687,270 Added 72.24%
1,638,609 $19 Million
Q1 2022

May 16, 2022

BUY
$16.79 - $20.88 $1.74 Million - $2.16 Million
103,656 Added 12.23%
951,339 $17.6 Million
Q4 2021

Feb 14, 2022

BUY
$15.65 - $21.5 $2.82 Million - $3.87 Million
180,009 Added 26.96%
847,683 $16.8 Million
Q3 2021

Nov 15, 2021

BUY
$10.69 - $18.2 $5.14 Million - $8.76 Million
481,269 Added 258.18%
667,674 $11 Million
Q2 2021

Oct 14, 2021

SELL
$14.34 - $18.67 $2.58 Million - $3.36 Million
-180,009 Reduced 49.13%
186,405 $3.41 Million
Q2 2021

Aug 16, 2021

BUY
$14.34 - $18.67 $2.59 Million - $3.37 Million
180,633 Added 97.23%
366,414 $6.7 Million
Q1 2021

Oct 14, 2021

SELL
$15.5 - $24.93 $2.79 Million - $4.49 Million
-180,009 Reduced 49.21%
185,781 $3.1 Million
Q1 2021

May 17, 2021

BUY
$15.5 - $24.93 $5.67 Million - $9.12 Million
365,790 New
365,790 $6.11 Million

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $986M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Commodore Capital LP Portfolio

Follow Commodore Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.